COMPANY
PRODUCTS
LATEST NEWS
INVESTOR INFO
CONTACT US
10-Oct-2008
EXTRAORDINARY GENERAL MEETINGS STATEMENT -- XTL NOTIFIES NASDAQ OF COMPLIANCE WITH MARKETPLACE RULE 4350(D)(2)
7-Oct-2008
XTL BIOPHARMACEUTICALS ANNOUNCES COMPLETION OF THE BICIFADINE PHASE 2B STUDY FOR DIABETIC NEUROPATHIC PAIN
2-Oct-2008
XTL BIOPHARMACEUTICALS EXTRAORDINARY GENERAL MEETINGS POSTPONED UNTIL OCTOBER 10, 2008
2008
2007
2006
2005
2004
2003
2002
2001
2000
